Treatment of Older Adults With Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of a multi-drug
regimen (which includes prednisone, vincristine, cytarabine, doxorubicin, 6 mercaptopurine,
and methotrexate) which is considered standard treatment for children and young adults with
acute lymphoblastic leukemia (ALL), in combination with PEG-asparaginase and clofarabine to
treat older adults with ALL. PEG-asparaginase has been used in chemotherapy treatment
regimens for both children and adults with ALL. Clofarabine has been used in chemotherapy
treatment regimens for children with ALL and has been shown to decrease the number of
leukemia cells. Participants with leukemia that has an abnormal chromosome, called the
Philadelphia chromosome, will also be given imatinib.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Enzon Pharmaceuticals, Inc. Genzyme, a Sanofi Company